Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZED1227 for persistent coeliac disease symptoms despite a gluten-free diet
ISRCTN79155276Phase 2Recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ZED1227 in celiac disease (6 cohorts), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Coeliac Disease Symptom Diary GI-specific Symptom Score. Started Mar 2024; status: recruiting.
02
Drugs
ZED1227
03
Conditions
celiac disease
Beyond the preview
Go deeper on ISRCTN79155276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79155276.